The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Additional Draws on Loan Facility

9 Sep 2014 07:00

RNS Number : 1156R
Amphion Innovations PLC
09 September 2014
 



Amphion Innovations plc

Additional Draws on Loan Facility

London and New York, 9 September 2014 - Amphion Innovations plc (LSE: AMP) ("Amphion" or the "Company"), the developer of medical and technology businesses, today announces that the Company has agreed terms for the draw-down of an additional four consecutive monthly tranches of $250,000 each (aggregating to $1 million) (each an "Additional Draw") under the loan facility announced on 5 June 2014 ("Facility"). The first Additional Draw was made on 5 September 2014.

The Additional Draws are on substantially the same terms as the Facility subject to the Lender receiving, on each Additional Draw, 78,035 simulated warrants in Kromek Group plc with an exercise price of 61.25 pence per share and 1,274,583 warrants in Amphion with an exercise price of 3.750 pence per share on the terms previously announced. The Lender has agreed to a reduced implementation fee on each Additional Draw of 6%.

The Additional Draws are to be used for working capital for Amphion and its Partner Companies.

 

For further information please contact

Amphion Innovations plcCharlie Morgan,+1 (212) 210 6224

Novella Communications Tim Robertson / Ben Heath+44 020 3151 7008Panmure Gordon Limited Freddy Crossley / Duncan Monteith (Corporate Finance)Charles Leigh-Pemberton (Corporate Broking)+44 020 7886 2500

Plumtree Capital Limited (Advisor to Amphion)

Stephen Austin

+44 207 183 2493

+1 646 568 7502

 

About Amphion Innovations plc Amphion (LSE: AMP) builds shareholder value in emerging companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

 

On the web: www.amphionplc.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQKFDQQBKDDCK
Date   Source Headline
8th Jun 20067:01 amRNSAppointment
6th Jun 20067:01 amRNSRe Agreement
5th Jun 20063:16 pmRNSThe Shafallah Center
2nd Jun 20065:01 pmRNSDr David Evans
1st Jun 20067:00 amRNSAnnual Report and Accounts
23rd May 20067:00 amRNSDirector/PDMR Shareholding
22nd May 20061:41 pmRNSDirector/PDMR Shareholding
19th May 20065:12 pmRNSDirector Share Transaction
15th Mar 20069:25 amRNSCompletion of a Financing
8th Mar 20067:04 amRNSFinal Results
2nd Mar 20069:12 amRNSMotif BioSciences
27th Feb 20064:56 pmRNSNotice of Results
23rd Feb 20067:02 amRNSRe: WellGen Financing
3rd Jan 20067:01 amRNSAdditional Investments
5th Dec 200512:48 pmRNSDirector Shareholding
10th Oct 20057:00 amRNSAcquires a stake
21st Sep 20057:00 amRNSStake in Spin-Out Company
30th Aug 20057:00 amRNSAmphion Invests in WellGen
25th Aug 20054:50 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.